Wie antikoaguliert man ältere und fragile Patienten?

Joerg Herold; Rupert Bauersachs

doi:10.1055/a-1547-4726

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie, Table of Contents

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie 2021; 8(03): 203-212
DOI: 10.1055/a-1547-4726

CME-Fortbildung

Wie antikoaguliert man ältere und fragile Patienten?

Authors

Joerg Herold
Rupert Bauersachs

Abstract

Mit zunehmendem Alter steigt das Risiko für Thrombosen, Blutungen und Nierenfunktionsstörungen. In diesem Artikel werden Daten sowohl aus neuen Studien als auch aus Subgruppenanalysen wegweisender Studien zu Wirksamkeit und Sicherheit von DOAK (direkten oralen Antikoagulanzien) bei fragilen Patienten mit Indikation zur Antikoagulation ausgewertet, um neue Erkenntnisse zu gewinnen und Wege für die Antikoagulation dieser Patienten zu beschreiben.

Schlüsselwörter

Antikoagulation - ältere Patienten - fragil - venöse Thromboembolien - Vorhofflimmern

Full Text

References

Literatur
1 López-Núñez JJ, Pérez-Andrés R, Di Micco P. et al. Direct oral anticoagulants or standard anticoagulant therapy in fragile patients with venous thromboembolism. TH Open 2019; 03: e67-e76
2 Reinecke H, Nabauer M, Gerth A. et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int 2015; 87: 200-209
3 Hart RG, Eikelboom JW, Brimble KS. et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013; 29: S71-S78
4 Olesen JB, Lip GY, Kamper AL. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. New Engl J Med 2012; 367: 625-635
5 Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation 2012; 125: 2649-2661
6 Yamagata K, Ishida K, Sairenchi T. et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney International 2007; 71: 159-166
7 Man-Son-Hing M, Nichol G, Lau A. et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-685
8 Donze J, Clair C, Hug B. et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125: 773-778
9 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507
10 Steffel J, Verhamme P, Potpara TS. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330-1393
11 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151
12 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891
13 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981-992
14 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2013; 369: 2093-2104
15 Kimachi M, Furukawa TA, Kimachi K. et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane Database Syst Rev 2017; 11: CD011373
16 Bauersachs R, Berkowitz SD. EINSTEIN Investigators. et al. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med 2010; 363: 2499-2510
17 Bauersachs RM, Lensing AW, Prins MH. et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 2014; 12: 25
18 Lim W, Dentali F, Eikelboom JW. et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-684
19 Gerlach AT, Pickworth KK, Seth SK. et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771-775
20 Spinler SA, Inverso SM, Cohen M. et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41
21 Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-1074
22 Ansell J, Hirsh J, Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S
23 Kleinow ME, Garwood CL, Clemente JL. et al. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 2011; 17: 523-530
24 Soliman EZ, Prineas RJ, Go AS. et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107
25 Eikelboom JW, Connolly SJ, Gao P. et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012; 21: 429-435
26 Go AS, Fang MC, Udaltsova N. et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in atrial Fibrillation (ATRIA) Study. Circulation 2009; 119: 1363-1369
27 Atar I, Konas D, Acikel S. et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 2006; 106: 47-51
28 Marinigh R, Lip GY, Fiotti N. et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010; 56: 827-837
29 Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124: 111-114
30 Reinecke H, Brand E, Mesters R. et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol JASN 2009; 20: 705-711
31 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-1678
32 Yao X, Shah ND, Sangaralingham LR. et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69: 2779-2790
33 Patti G, Pecen L, Lucerna M. et al. Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med 2019; 132: 749-757; e745
34 Bohm M, Ezekowitz MD, Connolly SJ. et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. J Am Coll Cardiol 2015; 65: 2481-2493
35 Fordyce CB, Hellkamp AS, Lokhnygina Y. et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation 2016; 134: 37-47
36 van Gorp RH, Schurgers LJ. New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs). Nutrients 2015; 7: 9538-9557
37 Anonym Anonym. Late-breaking science abstracts and featured science abstracts from the American Heart Association's scientific sessions 2019 and late-breaking abstracts in resuscitation science from the Resuscitation Science Symposium 2019.. Circulation 2019; 140: e965-e1011
38 Boersma LV, Schmidt B, Betts TR. et al. EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. Catheter Cardiovasc Interv 2016; 88: 460-465
39 Prins MH, Lensing AW, Bauersachs R. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21
40 Bauersachs RM, Herold J. Oral anticoagulation in the elderly and frail. Hamostaseologie 2020; 40: 74-83
41 Gangireddy C, Rectenwald JR, Upchurch GR. et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45: 335-341 discussion 341-332
42 Bauersachs RM. New oral anticoagulants and chronic kidney disease. Internist 2012; 53: 1431-1444
43 Bauersachs RM. Use of anticoagulants in elderly patients. Thromb Res 2012; 129: 107-115
44 Monreal M, Falga C, Valle R. et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119: 1073-1079
45 Lip GY, Frison L, Halperin JL. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180